A recent study demonstrated that bumetanide rescues core deficits of a mouse APOE4-related Alzheimer’s disease model and that bumetanide exposure significantly reduces Alzheimer’s disease risk in the population aged 65 and over [51]. This evidence concerns the gene APOE and early-onset autosomal dominant Alzheimer disease.